Hemoglobin S Allosteric Modulators for Oxygen Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease, mediated by sickle hemoglobin (HbS), are inadequate, as existing allosteric modulators do not effectively address the disorder's underlying issues of abnormal hemoglobin-mediated tissue and cellular oxygenation.
Innovation Solution
Development of compounds and pharmaceutical compositions that act as allosteric modulators of hemoglobin, specifically targeting hemoglobin S to increase oxygen affinity and treat associated oxygen deficiencies, including those with sickle cell anemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing allosteric modulators are used to treat sickle cell disease, then some therapeutic effect is achieved, but they do not effectively address the underlying issues of abnormal hemoglobin-mediated tissue and cellular oxygenation
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (substituted phenyl rings, heterocyclic groups, and functional groups at defined positions) that confer selective affinity for hemoglobin S. This localized structural design enables the compound to specifically target the abnormal hemoglobin molecule rather than acting as a general allosteric modulator, thereby effectively addressing the oxygenation issues specific to sickle cell disease.
Solution Approach 2:
The patent employs parameter changes by modifying the oxygen affinity of hemoglobin S through specific chemical interactions. The compounds are designed to bind to hemoglobin S and induce conformational changes that increase its oxygen affinity, shifting the oxygen dissociation curve to the left. This parameter change (increased oxygen affinity) directly addresses the underlying pathophysiology of sickle cell disease where reduced oxygen delivery to tissues is a key problem.
2Reliability
If compounds are designed to increase oxygen affinity of hemoglobin S, then oxygen deficiencies are addressed, but the complexity of the compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: a core phenyl or heterocyclic ring system, substituent groups at specific positions (R1-R6), and linker moieties. This segmented structure allows each component to contribute a specific function - the core provides binding affinity, the substituents modulate oxygen affinity, and the linkers provide structural flexibility. This modular design achieves the desired oxygen affinity enhancement while maintaining a manageable structural complexity through systematic organization of functional elements.
Solution Approach 2:
The patent uses intermediary structures - specifically the substituted phenyl and heterocyclic ring systems - that mediate between the requirement for high oxygen affinity and the need for manageable structural complexity. These intermediary molecular frameworks provide a stable platform for achieving the desired biophysical effect (increased oxygen affinity) without requiring excessively complex molecular architectures. The intermediaries act as structural bridges that translate chemical structure into the desired physiological effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed compounds effectively increase oxygen affinity of hemoglobin S, thereby addressing oxygen deficiencies and providing a therapeutic benefit for treating sickle cell disease and related disorders.
Implementation Method 1
compounds and pharmaceutical compositions suitable as allosteric modulators of hemoglobin
Implementation Method 2
Hemoglobin binds and releases oxygen through conformational changes
Data Source
AI summary
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.